Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
4(67%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
1
17%
Ph phase_1
4
67%

Phase Distribution

4

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

6

all time

Status Distribution
Active(4)
Completed(2)

Detailed Status

Active, not recruiting2
Completed2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (66.7%)
Phase 21 (16.7%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting233%
completed233%
recruiting233%

Recent Activity

4 active trials
Showing 5 of 6
recruitingphase_1

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT07539090
active_not_recruitingphase_3

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

NCT05059262
completedphase_1

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

NCT07158411
completedphase_1

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

NCT07158398
active_not_recruitingphase_1

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

NCT03069469
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07539090Phase 1

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

Recruiting
NCT05059262Phase 3

Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active Not Recruiting
NCT07158411Phase 1

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

Completed
NCT07158398Phase 1

Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate

Completed
NCT03069469Phase 1

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Active Not Recruiting
NCT06619561Phase 2

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6